[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529010":3},{"organization":4,"armGroups":7,"interventions":55,"overallOfficials":61,"centralContacts":61,"locations":86,"responsibleParty":107,"collaborators":61,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":61,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":61,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":89,"whyStopped":61,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Xijing Hospital of Digestive Diseases","OTHER",[8,14,20,25,30,35,40,45,50],{"label":9,"type":10,"description":11,"interventionNames":12},"Rabeprazloe+bismuth+amoxicillin+clarithromycin 14days","ACTIVE_COMPARATOR","14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid\u002F colloidal bismuth pectin 300mg bid\u002F colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.",[13],"Drug: Rabeprazloe+bismuth+amoxicillin+clarithromycin",{"label":15,"type":16,"description":17,"interventionNames":18},"Vonoprazan+amoxicillin+clarithromycin 14 days","EXPERIMENTAL","14D: V: vonoprazan 20mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.",[19],"Drug: Vonoprazan+amoxicillin+clarithromycin 14 days",{"label":21,"type":16,"description":22,"interventionNames":23},"Vonoprazan+amoxicillin+clarithromycin 7 days","7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.",[24],"Drug: Vonoprazan+amoxicillin+clarithromycin 7 days",{"label":26,"type":16,"description":27,"interventionNames":28},"Vonoprazan+tetracycline+furazolidone 14 days","14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.",[29],"Drug: Vonoprazan+tetracycline+furazolidone 14 days",{"label":31,"type":16,"description":32,"interventionNames":33},"Vonoprazan+tetracycline+furazolidone 7 days","7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.",[34],"Drug: Vonoprazan+tetracycline+furazolidone 7 days",{"label":36,"type":16,"description":37,"interventionNames":38},"Vonoprazan+amoxicillin+furazolidone 7 days","7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg tid; F: furazolidone 100mg bid.",[39],"Drug: Vonoprazan+amoxicillin+furazolidone 7 days",{"label":41,"type":16,"description":42,"interventionNames":43},"Vonoprazan+amoxicillin+tetracycline 14 days","7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg tid; T: tetracycline 500mg tid.",[44],"Drug: Vonoprazan+amoxicillin+tetracycline 14 days",{"label":46,"type":16,"description":47,"interventionNames":48},"Vonoprazan+amoxicillin 7 days","7D:V: vonoprazan 20mg bid; A:amoxicillin1000mg tid.",[49],"Drug: Vonoprazan+amoxicillin 7 days",{"label":51,"type":16,"description":52,"interventionNames":53},"Vonoprazan+amoxicillin 14 days","14D:V: vonoprazan 20mg bid; A:amoxicillin1000mg tid.",[54],"Drug: Vonoprazan+amoxicillin 14 days",[56,62,65,68,71,74,77,80,83],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"DRUG","Rabeprazloe+bismuth+amoxicillin+clarithromycin","PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid\u002F colloidal bismuth pectin 300mg bid\u002F colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.",[9],null,{"type":57,"name":15,"description":63,"armGroupLabels":64,"otherNames":61},"VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.",[15],{"type":57,"name":21,"description":66,"armGroupLabels":67,"otherNames":61},"VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.",[21],{"type":57,"name":26,"description":69,"armGroupLabels":70,"otherNames":61},"VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.",[26],{"type":57,"name":31,"description":72,"armGroupLabels":73,"otherNames":61},"VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.",[31],{"type":57,"name":36,"description":75,"armGroupLabels":76,"otherNames":61},"hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.",[36],{"type":57,"name":41,"description":78,"armGroupLabels":79,"otherNames":61},"hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.",[41],{"type":57,"name":46,"description":81,"armGroupLabels":82,"otherNames":61},"hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.",[46],{"type":57,"name":51,"description":84,"armGroupLabels":85,"otherNames":61},"hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.",[51],[87],{"facility":88,"status":89,"city":90,"state":91,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":100,"contacts":101},"Ying han","RECRUITING","Xi'an","Shaanxi","710032","China","CN",{"type":96,"coordinates":97},"Point",[98,99],108.92861,34.25833,{"lat":99,"lon":98},[102],{"name":103,"role":104,"phone":105,"phoneExt":61,"email":106},"Ying Han","CONTACT","+86-29-84771539","hanying1@fmmu.edu.cn",{"type":108,"investigatorFullName":109,"investigatorTitle":110,"investigatorAffiliation":5,"oldNameTitle":61,"oldOrganization":61},"PRINCIPAL_INVESTIGATOR","Han Ying","Prof","100529010","phase-4-standard-or-short-course-vonoprazan-non-bismuth-triple-therapy-or-high-dose-dual-therapy-versus-rabeprazole-bismuth-quadruple-therapy-for-primary-helicobacter-pylori-eradication-100529010",false,"NCT06168214","Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication: A Single-center, Randomised, Controlled Trial.","Inclusion Criteria:\n\n* Age 18-70 years, regardless of sex; chronic gastritis, peptic ulcer or dyspeptic symptoms, clear Hp infection (positive 13C-urea breath test); voluntary Hp eradication treatment; women of childbearing age are required to use a medically desirable form of contraception during the trial and for 1 month after the trial.\n\nExclusion Criteria:\n\n* Have contraindications to the study drug or are allergic to the study drug; have taken a PPI within 2 weeks and an antibiotic or bismuth within 4 weeks; pregnant and lactating women; and Have undergone upper gastrointestinal surgery; refluse to sign the informed consent document.",true,"ALL","18 Years","70 Years",{"count":123,"type":124},1404,"ESTIMATED","INTERVENTIONAL",[127],"PHASE4","The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are:\n\n* Main indicators: the eradication rate of Helicobacter pylori for eradication.\n* Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.",[130],"the Eradication Rates of Helicobacter Pylori",[132],"Helicobacter pylori ; Vonoprazan","2024-08-09",{"date":135,"type":136},"2024-08-13","ACTUAL",{"date":138,"type":136},"2023-09-04",{"date":140,"type":124},"2024-12-25",{"name":5,"class":6},1]